MedTrace Logo

A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients

NCT00005764 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2005-06-24

No results posted yet for this study

Summary

The purpose of this study is to see if the findings of increased lactic acid and abnormal fat distribution get better when d4T is replaced with abacavir, abacavir plus lamivudine, or Combivir (a pill containing lamivudine plus zidovudine) in HIV-positive patients taking anti-HIV therapy including stavudine (d4T).

Conditions

  • HIV Infections
  • Lipodystrophy

Interventions

DRUG

Lamivudine/Zidovudine

DRUG

Abacavir sulfate

DRUG

Lamivudine

Sponsors & Collaborators

  • Glaxo Wellcome

    lead INDUSTRY

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005764 on ClinicalTrials.gov